TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2006773

Group type: EXPERIMENTAL
Intervention: Oral slow-release theophylline (4.7 to 16.6 mg/kg/day, divided into two doses)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29343283

Group type: EXPERIMENTAL
Intervention: Classroom Communication Resource (CCR) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice (no-CCR control)
Number of subjects: 0
Study: 27094802

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (non-users of rosuvastatin)
Number of subjects: 50
Study: 24291272

Group type: EXPERIMENTAL
Intervention: Transcatheter AVR
Number of subjects: 275

Group type: COMPARATOR
Intervention: Surgical AVR
Number of subjects: 275
Study: 22739802

Group type: EXPERIMENTAL
Intervention: Soy bread (3 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Soy beverage (3 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Soy bread
Number of subjects: 20

Group type: COMPARATOR
Intervention: Soy beverage
Number of subjects: 20
Study: 19846407

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study: 18950325

Group type: EXPERIMENTAL
Intervention: Callander blade
Number of subjects: 100

Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both blades
Number of subjects: 100
Study: 16883907

Group type: EXPERIMENTAL
Intervention: Tangshenling (TSL) combined with telmisartan
Number of subjects: 81

Group type: COMPARATOR
Intervention: Telmisartan alone
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups (TSL + telmisartan and telmisartan alone)
Number of subjects: 81
Study: 12759473

Group type: EXPERIMENTAL
Intervention: Radio-frequency (RF) thermal ablation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Percutaneous ethanol injection (PEI)
Number of subjects: 102
Study: 10864482

Group type: EXPERIMENTAL
Intervention: Computer-assisted peer teaching
Number of subjects: 77

Group type: COMPARATOR
Intervention: Computer-assisted learning alone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups (computer-assisted peer teaching and computer-assisted learning alone)
Number of subjects: 77
Study: 8688399

Group type: EXPERIMENTAL
Intervention: Ritodrine sustained release capsules (40 mg, 3 times a day for 7 days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo capsules (identical to ritodrine)
Number of subjects: 95
Study: 1839656

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg or 5.0 mg/day
Number of subjects: 2702

Group type: COMPARATOR
Intervention: Placebo (during pretreatment phase)
Number of subjects: 2702
Study: 6350745

Group type: EXPERIMENTAL
Intervention: Hospice intervention (not specified in detail)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: McGill Pain scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CES‐D Depression scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Satisfaction with Care scale
Number of subjects: 0
Study: 31607019

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided erector spinae block combined with oral drug pregabalin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral drug pregabalin
Number of subjects: 60
Study: 29394969

Group type: EXPERIMENTAL
Intervention: Lactulose plus rifaximin 550 mg twice daily for 10 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Lactulose alone 30 ml thrice daily for 10 days
Number of subjects: 130
Study: 27685348

Group type: COMPARATOR
Intervention: Massed practice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Distributed practice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups (massed and distributed)
Number of subjects: 10
Study: 24879581

Group type: EXPERIMENTAL
Intervention: Local bone grafting
Number of subjects: 81

Group type: COMPARATOR
Intervention: Allograft bone
Number of subjects: 81
Study: 22170364

Group type: COMPARATOR
Intervention: DASH diet (28 g beef/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: BOLD diet (113 g beef/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: BOLD+ diet (153 g beef/d)
Number of subjects: 36
Study: 19773670

Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Weight training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 17334957

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 372

Group type: COMPARATOR
Intervention: Rizatriptan 10 mg
Number of subjects: 372
Study: 15759245

Group type: EXPERIMENTAL
Intervention: 350G magnet
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 23
Study: 12792353

Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI) treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-protease inhibitor (non-PI) treatment
Number of subjects: 51
Study: 10577698

Group type: COMPARATOR
Intervention: Standard radiotherapy, 60 Gy in 30 fractions in 6 weeks (R6)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Accelerated radiotherapy, 60 Gy in 30 fractions in 3 weeks (R3)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Standard radiotherapy with carboplatin 70 mg/m2/day for 5 days during weeks 1 and 5 (R6C)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy with carboplatin 70 mg/m2/day for 5 days during week 1 (R3C)
Number of subjects: 204
Study: 8950879

Group type: EXPERIMENTAL
Intervention: Alendronate (initially 5 mg daily, increased to 10 mg daily at 24 months)
Number of subjects: 2027

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 2027
Study: 2031498

Group type: EXPERIMENTAL
Intervention: Intervention in TOHP (Trials of Hypertension Prevention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention in HPT (Hypertension Prevention Trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention in TOHP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention in HPT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (black control subjects)
Number of subjects: 0
Study: 6783861

Group type: EXPERIMENTAL
Intervention: Combination of beta-blockers and diuretic agents (Cardiotensin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sustained-release form of beta-blockers and diuretic agents
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of beta-blockers and diuretic agents
Number of subjects: 60
Study: 31490300

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone 10 mg/mL
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone 40 mg/mL
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 32
Study: 30886139

Group type: EXPERIMENTAL
Intervention: Patients with hemoglobin (Hb) ≥ 12 g/dl
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Patients with MGUS-like profile
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Patients with hemoglobin (Hb) ≥ 12 g/dl including depth of response (and MRD)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Patients with MGUS-like signature including depth of response (and MRD)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Patients with MRD negativity
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) rate at 10 years
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Disease control at 5 years
Number of subjects: 435
Study: 28351408

Group type: EXPERIMENTAL
Intervention: SMS intervention (sent for five rounds every two weeks)
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: SMS intervention
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 3600
Study: 26971190

Group type: EXPERIMENTAL
Intervention: Endorectal coil (ERC) MRI
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard non-endorectal coil (non-ERC) MRI
Number of subjects: 49

Group type: COMPARATOR
Intervention: Augmented non-endorectal coil (non-ERC) MRI
Number of subjects: 49
Study: 25099612

Group type: EXPERIMENTAL
Intervention: Baseline 25-hydroxyvitamin D levels
Number of subjects: 256
Study: 22708608

Group type: EXPERIMENTAL
Intervention: Transdermal alcohol concentration (TAC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Breath alcohol concentration (BrAC)
Number of subjects: 22
Study: 19477972

Group type: EXPERIMENTAL
Intervention: Occlusal adjustment (treatment group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Grinding that did not affect occlusal contacts (control group)
Number of subjects: 112
Study: 17264719

Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalation at 0.5-1 vol% end-tidal concentrations
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (absence of sevoflurane)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalation
Number of subjects: 5
Study: 15621654

Group type: EXPERIMENTAL
Intervention: Experimental analysis using a prototype measuring device for rehabilitation evaluation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-pathological subjects
Number of subjects: 2
Study: 11927756

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 54

Group type: COMPARATOR
Intervention: Psychological treatment conditions (collapsed for this study)
Number of subjects: 54
Study: 9830233

Group type: EXPERIMENTAL
Intervention: Alendronate sodium 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7860156

Group type: COMPARATOR
Intervention: Hygiene education intervention focusing on personal and domestic hygiene practices, including handwashing and disposal of faeces, conducted over 3 months.
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2082
Study: 2476624

Group type: EXPERIMENTAL
Intervention: Felodipine (1 mg, intravenously)
Number of subjects: 23
Study: 6181

Group type: EXPERIMENTAL
Intervention: Bacampicillin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 9
Study: 31239466

Group type: EXPERIMENTAL
Intervention: Alternative model with distance-based connection probability
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watts-Strogatz (WS) model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative model
Number of subjects: 0
Study: 27855270

Group type: EXPERIMENTAL
Intervention: SRP + LLLT
Number of subjects: 22

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 22
Study: 26114854

Group type: EXPERIMENTAL
Intervention: 12 week multi-disciplinary lifestyle intervention (physical activity, nutrition education, cognitive behavioural therapy)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 43
Study: 23866761

Group type: EXPERIMENTAL
Intervention: Green tea mouthwash
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 44
Study: 22146117

Group type: EXPERIMENTAL
Intervention: NLP therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Gourmet cooking course
Number of subjects: 56
Study: 19203221

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived cells (BMC) therapy
Number of subjects: 0
Study: 16702369

Group type: EXPERIMENTAL
Intervention: Cytology (ASCUS+)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: PCR for carcinogenic HPV
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Combination testing (carcinogenic HPV testing or cytology)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: HC2 alone
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: ASCUS+ cytology
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: HC2
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Combination testing
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: HPV16 positivity
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Overall incidence of posttreatment CIN2+
Number of subjects: 610
Study: 15274670

Group type: EXPERIMENTAL
Intervention: KC 11458 (8 mg t.d.s. for 8 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 11742880

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 22
Study: 8976243

Group type: EXPERIMENTAL
Intervention: Electrosurgical vaporization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional loop resection
Number of subjects: 0
Study: 8214733

Group type: EXPERIMENTAL
Intervention: Benzyl alcohol 0.9% in normal saline
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine 1% with preservative
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (no previous drug injected)
Number of subjects: 280
Study: 3446416

Group type: EXPERIMENTAL
Intervention: Salbutamol ointment (1% salbutamol base in white soft paraffin) b.d. for 2 weeks
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salbutamol slow-release spandets
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30857385

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion during sevoflurane anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline infusion during sevoflurane anesthesia
Number of subjects: 60
Study: 28705571

Group type: EXPERIMENTAL
Intervention: Biodegradable interference screw fixation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All-inside cortical button fixation
Number of subjects: 33
Study: 25513965

Group type: EXPERIMENTAL
Intervention: Combination therapy of ticagrelor (90 mg/bid) and warfarin
Number of subjects: 296

Group type: COMPARATOR
Intervention: Triple antithrombosis therapy (clopidogrel + aspirin + warfarin)
Number of subjects: 296
Study: 23314164

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 86
Study: 21654092

Group type: EXPERIMENTAL
Intervention: Trunk balance exercises in addition to standard trunk flexibility exercises
Number of subjects: 79

Group type: COMPARATOR
Intervention: Strengthening exercises in addition to standard trunk flexibility exercises
Number of subjects: 79
Study: 18486746

Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude spinal manipulation (SM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Prethrust positioning and joint loading
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 72
Study: 16537707

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug (NSAID) use
Number of subjects: 1723

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drug (NSAID) non-use
Number of subjects: 1723
Study: 15342298

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study: 11094401

Group type: EXPERIMENTAL
Intervention: Attention Process Training (APT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Brain Injury Education
Number of subjects: 14
Study: 9347497

Group type: EXPERIMENTAL
Intervention: 3% diclofenac in 2.5% hyaluronan
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2.5% hyaluronan
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3% viscous lidocaine
Number of subjects: 60
Study: 8239849

Group type: EXPERIMENTAL
Intervention: Nabumetone, 1000 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Ibuprofen, 600 mg four times daily
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Ibuprofen plus Misoprostol, 600 mg and 200 micrograms four times daily
Number of subjects: 171
Study: 3898700

Group type: EXPERIMENTAL
Intervention: Diazepam (0.185 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diazepam (0.185 mg/kg) plus droperidol (0.09 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diazepam (0.135 mg/kg) plus droperidol (0.09 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (Diazepam alone)
Number of subjects: 90
Study: 31132765

Group type: EXPERIMENTAL
Intervention: Smartphone app for toothbrushing
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (manual toothbrush without app)
Number of subjects: 49
Study: 30356312

Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27474375

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic prostatectomy
Number of subjects: 326

Group type: COMPARATOR
Intervention: Radical retropubic prostatectomy
Number of subjects: 326
Study: 24599463

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over right DLPFC
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS (control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cathodal tDCS over homologous contralateral area
Number of subjects: 24
Study: 22006202

Group type: EXPERIMENTAL
Intervention: tofacitinib 3 mg twice daily
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice daily
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg twice daily
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: tofacitinib 15 mg twice daily
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: tofacitinib 20 mg/day
Number of subjects: 507

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 507
Study: 19547993

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pimecrolimus
Number of subjects: 40
Study: 18049022

Group type: EXPERIMENTAL
Intervention: 75 mg/day dipyridamole
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 300 mg/day dipyridamole
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no dipyridamole)
Number of subjects: 28
Study: 16218039

Group type: EXPERIMENTAL
Intervention: Gamma-probe guided revision thyroidectomy (GGRT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional revision thyroidectomy (CRT)
Number of subjects: 25
Study: 12124485

Group type: EXPERIMENTAL
Intervention: Automatic detection of CAD using image registration and voxel to voxel statistical comparisons
Number of subjects: 104

Group type: COMPARATOR
Intervention: Three expert observers
Number of subjects: 104
Study: 11004845

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) in individuals with chronic silica exposure
Number of subjects: 15
Study: 8993092

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 227

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 227
Study: 1618361

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 114

Group type: COMPARATOR
Intervention: no antihypertensive therapy (control)
Number of subjects: 114
Study: 6369816

Group type: EXPERIMENTAL
Intervention: PVP iodine prophylaxis
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 30686326

Group type: EXPERIMENTAL
Intervention: Robot-assisted reach training with assist-as-needed (RT-AAN)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Robot-assisted reach training with guidance force (RT-G)
Number of subjects: 38
Study: 29272062

Group type: EXPERIMENTAL
Intervention: Intensive Insulin Treatment (IIT) - glargine/glulisine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Initial Combined Oral Antidiabetic Drug (COAD) therapy - glimepiride/metformin
Number of subjects: 97
Study: 26669628

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 1463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1463
Study: 24450500

Group type: EXPERIMENTAL
Intervention: High whey protein, leucine-enriched supplement (20 g whey protein, 3g total leucine, 150 kcal)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Iso-caloric milk protein control (6g milk protein)
Number of subjects: 19
Study: 22500661

Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate 1200 mg/day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 20116702

Group type: EXPERIMENTAL
Intervention: Therapeutic laser (4 J/cm² energy density, diode wavelength of 810 nm, output power of 100 mW)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard management (control group)
Number of subjects: 30
Study: 17573520

Group type: EXPERIMENTAL
Intervention: Prophylactic tadalafil (10 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prophylactic dexamethasone (8 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 15964386

Group type: EXPERIMENTAL
Intervention: sirolimus, tacrolimus, low-dose rabbit antithymocyte globulin, and glucocorticoids
Number of subjects: 31

Group type: COMPARATOR
Intervention: cyclosporine, mycophenolate mofetil, and glucocorticoids
Number of subjects: 31
Study: 12691271

Group type: EXPERIMENTAL
Intervention: Braun Oral-B 3D Excel (D17)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Colgate Actibrush
Number of subjects: 74
Study: 10597853

Group type: EXPERIMENTAL
Intervention: Competition season training in lightweight rowers
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 22
Study: 8537277

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg once daily for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 40
Study: 30506227

Group type: EXPERIMENTAL
Intervention: Calcium sodium phosphosilicate paste (NovaMin®)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1 W, 10 Hz, 85 J/cm2)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control-placebo
Number of subjects: 70
Study: 27936684

Group type: EXPERIMENTAL
Intervention: Jug n 4 allergen
Number of subjects: 25
Study: 26482694

Group type: EXPERIMENTAL
Intervention: Structured physical activity (PA)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Health education promoting successful aging (SA)
Number of subjects: 333
Study: 23992515

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 μg
Number of subjects: 17135

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 μg
Number of subjects: 17135

Group type: COMPARATOR
Intervention: Tiotropium HandiHaler 18 μg
Number of subjects: 17135